KPV vs BPC-157: What the Research Shows
KPV and BPC-157 side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider KPV if…
- you are tested in sport and want to avoid a WADA-prohibited substance: BPC-157 is prohibited by WADA at all times (check KPV's own status separately)[2]
Consider BPC-157 if…
- you want any human reports (a small, uncontrolled report): 14 of 16 patients (87.5%) reported relief with BPC 157 alone or combined with thymosin beta-4 (TB4).[15]
What they have in common
Spec comparison
Showing 9 of 12 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026 are the same or both unknown.
| Field | KPV | BPC-157 |
|---|---|---|
| Class | Anti-inflammatory tripeptide | Gastric pentadecapeptide |
| Also called | Lys-Pro-Val, alpha-MSH fragment | BPC, body protection compound, Pentadecapeptide BPC 157 |
| Category | Healing & recovery | Healing & recovery |
| FDA status | PCAC voted 8–6 for 503A (Jul 2026) | PCAC voted 8–6 for 503A (Jul 2026) |
| PCAC vote, Jul 2026 | PCAC voted 8–6 for the 503A list (Jul 2026); not finalized | PCAC voted 8–6 for the 503A list (Jul 2026); not finalized |
| WADA | WADA status unclearKPV: This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. | Prohibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 |
| Evidence strength | Animal evidence, 2 of 4Strongest: Inflammatory bowel diseases 2008, PMID 18092346 | Human observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143 |
| Human studies we summarised | 0 human (0 randomized or controlled) of 9 summarised | 3 human (0 randomized or controlled) of 25 summarised |
| Typical study doses | Not reported in study abstractsPubMed search, 11 Oct 2026 |
|
| Vial sizes sold | 5 mg, 10 mg, 20 mg | 2 mg, 5 mg, 10 mg, 20 mg |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Sold mixed: KLOW
These blends put both in one vial. The blend calculator works out the dose of each component per draw. Evidence for the combination: No studies tested these together (PubMed search: 1 result, 2 Oct 2026).
Both are mostly animal peptides, but not equally so
A BPC-157 bladder-pain pilot reported complete resolution of symptoms after one treatment in 10 of 12 patients.[12]
The same pilot reported no dropouts and no adverse events. As a small pilot it cannot show that the injection caused the improvement.[12]
In a mouse DSS-colitis model, KPV led to earlier recovery and stronger body-weight regain.[3]
In cell experiments, KPV and gamma-MSH dose-dependently inhibited NFkB, matrix metalloproteinase-9 activity, IL8 and eotaxin secretion.[19]
In rats, BPC 157 healed cysteamine-induced colitis and colon-colon anastomosis.[20]
A systematic review of BPC-157 in sports medicine included 36 studies, 35 preclinical and 1 clinical.[16]
Regulatory, sport and pharmacokinetic contrasts
FDA's compounding safety-risk text says it has identified no, or only limited, safety-related information for the proposed routes of administration of BPC-157.[21]
WADA's prohibited list names BPC-157 in its S0 class.[2]
WADA defines that S0 class as any pharmacological substance not addressed elsewhere on the list and with no current approval by a government health authority for human therapeutic use.[2]
In rats and beagle dogs, the elimination half-life of prototype BPC157 was less than 30 min.[10]
In an ex vivo skin test, KPV permeation by simple passive diffusion was below the detection limit (0.01 ug/mL).[22]
Common questions
Is KPV better than BPC-157?
No head-to-head work is cited. BPC-157 has a small human bladder-pain pilot (10 of 12 patients reported complete resolution); no human KPV study is cited.[12]
Can you take KPV and BPC-157 together?
No study of the pair is cited, and FDA says it lacks important safety information on KPV, including whether it would cause harm if given to humans.[21]
Which is better for gut health, KPV or BPC-157?
Both have animal colitis work only: in mice KPV led to earlier recovery from induced colitis, and in rats BPC-157 healed cysteamine-induced colitis.[3]
Sources
- 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
- 4PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) (132 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (alpha-MSH[tiab] OR melanocortin[tiab] OR colitis[tiab] OR inflammat*[tiab]) (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (clinical trial[pt] OR randomized[tiab] OR patients[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
- 9Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
- 10Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
- 11Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
- 12Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
- 13Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 14PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.Alternative therapies in health and medicine · 2021PMID 34324435Accessed 2 Oct 2026
- 16Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
- 17Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 18PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 19Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.International journal of physiology, pathophysiology and pharmacology · 2012PMID 22837805Accessed 2 Oct 2026
- 20Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2013PMID 24304574Accessed 2 Oct 2026
- 21Official web pageOfficial web page · web page
- 22Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.Journal of pharmaceutical sciences · 2017PMID 28343991Accessed 2 Oct 2026
Found an error? Report a correction.